Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Epirubicin/Vinorelbine in Advanced Breast Cancer
NCT00176488Phase 2Terminated
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Jun 2003
- Primary completion
- Oct 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin and vinorelbine in breast cancer, sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Efficacy of the Sequential Use of Epirubicin Followed by Vinorelbine at 10 years. Started Jun 2003; status: terminated.
02
Drugs
epirubicinvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00176488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176488.